BGLC - CIK 0001737523
BioNexus Gene Lab Corp trades as BGLC. In its fiscal 2025 annual report the company posted revenue of $7.42M, down 21.9% from the prior year and net income of -$2.98M. This page tracks BioNexus Gene Lab Corp through 140 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 7 fiscal years BioNexus Gene Lab Corp's revenue grew from $212.33K to $7.42M, a compound annual growth rate of 66.2%. Net profit margin compressed from 12.5% to -40.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-15 |
| Annual report | 10-K | 2026-04-14 |
| NT 10-K | - | 2026-03-31 |
| Major company event | 8-K | 2026-03-17 |
| Major company event | 8-K | 2026-02-23 |
| Major company event | 8-K | 2026-02-03 |
| Major company event | 8-K | 2025-12-30 |
| Major company event | 8-K | 2025-12-23 |
The largest companies sharing BioNexus Gene Lab Corp's SEC industry classification (services-medical laboratories).
BioNexus Gene Lab Corp reported revenue of $7.42M for fiscal year 2025, a decrease of 21.9% year over year.
In its latest fiscal year BioNexus Gene Lab Corp reported a net loss of $2.98M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.